Late-Stage CRO INC Research/inVentiv Health Provides an Attractive Entry Point but With Higher Risk
We are initiating coverage of narrow-moat INC Research/inVentiv Health with a fair value estimate at $53 per share. INC Research’s 2017 merger with inVentiv Health launched the company into the upper echelon of global, late-stage contract research organizations. We believe the new entity, INC Research/inVentiv Health, is one of the few CROs with the global infrastructure necessary to compete for big biopharma strategic partnerships. Competition for these global contracts is limited to the seven ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.